Replimune Group Inc
REPL5.415USD
-2.185-28.75%
交易中 （美东）报价延迟15分钟
417.42M总市值
亏损市盈率 TTM
关于 Replimune Group Inc 公司
Replimune Group, Inc. 是一家临床阶段生物技术公司，致力于开发新型溶瘤免疫疗法。该公司专有的 RPx 平台基于强效的 HSV-1 骨架，旨在最大限度地提高免疫原性细胞死亡和诱导全身抗肿瘤免疫反应。RP1（vusolimogene oderparepvec）是其主要候选产品，基于专有的单纯疱疹病毒株，经过工程改造，并在基因上配备了融合蛋白（GALV-GP R-）和 GM-CSF，旨在最大限度地提高肿瘤杀伤力、肿瘤细胞死亡的免疫原性和激活全身抗肿瘤免疫反应。该公司还在开发其他候选产品 RP2 和 RP3，以增强抗肿瘤免疫反应，旨在治疗其他肿瘤类型，包括传统上免疫反应较弱的肿瘤类型。 RP2 还表达抗 CTLA-4 抗体样分子，以及 GALV-GP R 和 GM-CSF。
公司简介
公司代码REPL
公司名称Replimune Group Inc
上市日期Jul 20, 2018
CEODr. Sushil Patel, Ph.D.
员工数量479
证券类型Ordinary Share
年结日Jul 20
公司地址500 Unicorn Park Dr
城市WOBURN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编01801-3377
电话17812229600
网址https://www.replimune.com/
公司代码REPL
上市日期Jul 20, 2018
CEODr. Sushil Patel, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Philip Astley-Sparke
Mr. Philip Astley-Sparke
Executive Chairman of the Board
Executive Chairman of the Board
1.32M
+5.99%
Dr. Sushil Patel, Ph.D.
Dr. Sushil Patel, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
81.28K
-55.32%
Ms. Emily Luisa Hill
Ms. Emily Luisa Hill
Chief Financial Officer
Chief Financial Officer
36.86K
-32.20%
Dr. Konstantinos Xynos, M.D.
Dr. Konstantinos Xynos, M.D.
Chief Medical Officer
Chief Medical Officer
33.93K
-17.52%
Mr. Christopher (Chris) Sarchi
Mr. Christopher (Chris) Sarchi
Chief Commercial Officer
Chief Commercial Officer
27.88K
-78.27%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Independent Director
Independent Director
6.67K
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Mr. Dieter Weinand
Mr. Dieter Weinand
Lead Independent Director
Lead Independent Director
--
--
Ms. Veleka Peeples-Dyer
Ms. Veleka Peeples-Dyer
Independent Director
Independent Director
--
--
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Philip Astley-Sparke
Mr. Philip Astley-Sparke
Executive Chairman of the Board
Executive Chairman of the Board
1.32M
+5.99%
Dr. Sushil Patel, Ph.D.
Dr. Sushil Patel, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
81.28K
-55.32%
Ms. Emily Luisa Hill
Ms. Emily Luisa Hill
Chief Financial Officer
Chief Financial Officer
36.86K
-32.20%
Dr. Konstantinos Xynos, M.D.
Dr. Konstantinos Xynos, M.D.
Chief Medical Officer
Chief Medical Officer
33.93K
-17.52%
Mr. Christopher (Chris) Sarchi
Mr. Christopher (Chris) Sarchi
Chief Commercial Officer
Chief Commercial Officer
27.88K
-78.27%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Independent Director
Independent Director
6.67K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月27日 周日
更新时间: 7月27日 周日
持股股东
股东类型
持股股东
持股股东
占比
Baker Bros. Advisors LP
14.20%
T. Rowe Price Associates, Inc.
13.79%
BlackRock Institutional Trust Company, N.A.
6.75%
Redmile Group, LLC
6.30%
Forbion Capital Partners
5.02%
Other
53.95%
持股股东
持股股东
占比
Baker Bros. Advisors LP
14.20%
T. Rowe Price Associates, Inc.
13.79%
BlackRock Institutional Trust Company, N.A.
6.75%
Redmile Group, LLC
6.30%
Forbion Capital Partners
5.02%
Other
53.95%
股东类型
持股股东
占比
Investment Advisor
36.07%
Hedge Fund
31.49%
Investment Advisor/Hedge Fund
26.65%
Venture Capital
9.20%
Individual Investor
3.02%
Research Firm
2.61%
Bank and Trust
0.34%
Pension Fund
0.23%
Insurance Company
0.03%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
374
87.33M
112.37%
-11.99M
2025Q1
385
87.62M
114.03%
-12.35M
2024Q4
379
83.57M
108.59%
-8.22M
2024Q3
364
75.43M
109.54%
-13.17M
2024Q2
356
76.19M
113.04%
-8.45M
2024Q1
339
72.12M
117.78%
-11.10M
2023Q4
328
71.51M
121.06%
+610.98K
2023Q3
311
68.80M
117.09%
+4.78M
2023Q2
308
66.67M
115.61%
+3.48M
2023Q1
306
60.20M
107.84%
+2.81M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
11.05M
14.33%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
10.73M
13.91%
-114.25K
-1.05%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.25M
6.81%
+493.29K
+10.36%
Mar 31, 2025
Redmile Group, LLC
4.90M
6.35%
-7.00K
-0.14%
Mar 31, 2025
Forbion Capital Partners
3.91M
5.07%
-60.97K
-1.54%
Mar 31, 2025
The Vanguard Group, Inc.
3.82M
4.96%
+232.85K
+6.49%
Mar 31, 2025
Tang Capital Management, LLC
2.90M
3.76%
+200.00K
+7.41%
Mar 31, 2025
Marshall Wace LLP
2.49M
3.23%
+1.59M
+177.59%
Mar 31, 2025
Sofinnova Investments, Inc
2.48M
3.22%
-669.58K
-21.26%
Mar 31, 2025
State Street Global Advisors (US)
2.40M
3.11%
+194.00K
+8.80%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Tema Oncology ETF
0.53%
ALPS Medical Breakthroughs ETF
0.48%
SPDR S&P Biotech ETF
0.19%
iShares Micro-Cap ETF
0.14%
T Rowe Price Small-Mid Cap ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
JPMorgan Fundamental Data Science Small Core ETF
0.1%
Optimize Strategy Index ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.08%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.85%
Tema Oncology ETF
占比0.53%
ALPS Medical Breakthroughs ETF
占比0.48%
SPDR S&P Biotech ETF
占比0.19%
iShares Micro-Cap ETF
占比0.14%
T Rowe Price Small-Mid Cap ETF
占比0.14%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.11%
JPMorgan Fundamental Data Science Small Core ETF
占比0.1%
Optimize Strategy Index ETF
占比0.08%
ProShares Ultra Nasdaq Biotechnology
占比0.08%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
